Carl Quintanilla Posted On X "GOLDMAN: "We update our market model for Obesity therapeutics and now forecast total worldwide sales of .. $130B in 2030, an increase from our prior $100B forecast. .. For $LLY, we now forecast revenues for the company's AOM portfolio .. in 2024/2027/2030 at $5.3B, $27.6B and $56.6B, representing an increase from $4.7B, $28.2B and $49.7B prior.; Ups target to $785 (prior $740)"
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has updated its market model for obesity therapeutics, forecasting total worldwide sales to reach $130 billion by 2030, up from a previous estimate of $100 billion. For Eli Lilly (LLY), the revenue forecast for its AOM portfolio has been increased for 2024, 2027, and 2030, with a new price target of $785, up from $740.
May 30, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has increased its revenue forecasts for Eli Lilly's AOM portfolio for 2024, 2027, and 2030, and raised the price target to $785 from $740.
The updated revenue forecasts and increased price target from Goldman Sachs are likely to positively impact Eli Lilly's stock price in the short term. The significant increase in the market model for obesity therapeutics further supports this positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100